Advertisement

Sequential therapy of portal vein embolization and systemic chemotherapy for locally advanced perihilar biliary tract cancer

Published:September 02, 2022DOI:https://doi.org/10.1016/j.ejso.2022.08.035

      Abstract

      Background

      Curative resection is the only potential treatment for cure in patients with perihilar biliary tract cancer (PBTC). However, post hepatectomy liver failure (PHLF) due to insufficient future liver remnant volume (FRLV) remains a lingering risk even after portal vein embolization (PVE). This study aimed to investigate the feasibility and efficacy of a sequential treatment strategy consisting of PVE followed by preoperative chemotherapy before surgery.

      Methods

      Between April 2019 and December 2021, 15 patients with locally advanced PBTC (LA-PBTC) underwent sequential treatment consisting of PVE followed by preoperative chemotherapy. The feasibility and efficacy, including resection rate, changes of FRLV, and chemotherapeutic effect, were investigated retrospectively.

      Results

      Thirteen of 15 patients (86.6%) underwent curative resection. The median duration time between PVE and surgery was 144 days. FRLV/TLV ratio was 31.3% at prePVE, 38.4%, at two weeks after PVE, and 45.7% before surgery, respectively. There was significant increase in FRLV/TLV ratio two weeks after PVE. Additional increase in FRLV/TLV ratio was significantly achieved before surgery. PHLF occurred in 5 patients (38.4%). Pathological complete response was found in 2 of 13 patients (15.3%).

      Conclusions

      Sequential PVE and systemic chemotherapy contribute to the sufficient hypertrophy of FRLV without compromising resectability in patients with LA-PBTC.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Farges O.
        • Regimbeau J.M.
        • Fuks D.
        • et al.
        Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma.
        Br J Surg. 2013; 100: 274-283
        • Nagino M.
        • Ebata T.
        • Yokoyama Y.
        • et al.
        Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections.
        Ann Surg. 2013; 258: 129-140
        • Ribero D.
        • Zimmitti G.
        • Aloia T.A.
        • et al.
        Preoperative cholangitis and future liver remnant volume determine the risk of liver failure in patients undergoing resection for hilar cholangiocarcinoma.
        J Am Coll Surg. 2016; 223: 87-97
        • Olthof P.B.
        • Wiggers J.K.
        • Groot Koerkamp B.
        • et al.
        Postoperative liver failure risk score: identifying patients with resectable perihilar cholangiocarcinoma who can benefit from portal vein embolization.
        J Am Coll Surg. 2017; 225: 387-394
        • Olthof P.B.
        • Aldrighetti L.
        • Alikhanov R.
        • et al.
        Portal vein embolization is associated with reduced liver failure and mortality in high-risk resections for perihilar cholangiocarcinoma.
        Ann Surg Oncol. 2020; 27: 2311-2318
        • Kubota K.
        • Makuuchi M.
        • Kusaka K.
        • et al.
        Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors.
        Hepatology. 1997; 26: 1176-1181
        • Kishi Y.
        • Abdalla E.K.
        • Chun Y.S.
        • et al.
        Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry.
        Ann Surg. 2009; 250: 540-548
        • Abdalla E.K.
        • Barnett C.C.
        • Doherty D.
        • Curley S.A.
        • Vauthey J.N.
        Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization.
        Arch Surg. 2002; 137 (; discussion 680-671): 675-680
        • Madoff D.C.
        • Gaba R.C.
        • Weber C.N.
        • Clark T.W.
        • Saad W.E.
        Portal venous interventions: state of the art.
        Radiology. 2016; 278: 333-353
        • Yokoyama Y.
        • Nishio H.
        • Ebata T.
        • Igami T.
        • Sugawara G.
        • Nagino M.
        Value of indocyanine green clearance of the future liver remnant in predicting outcome after resection for biliary cancer.
        Br J Surg. 2010; 97: 1260-1268
        • Nagino M.
        • Kamiya J.
        • Nishio H.
        • Ebata T.
        • Arai T.
        • Nimura Y.
        Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up.
        Ann Surg. 2006; 243: 364-372
        • Yamashita S.
        • Sakamoto Y.
        • Yamamoto S.
        • et al.
        Efficacy of preoperative portal vein embolization among patients with hepatocellular carcinoma, biliary tract cancer, and colorectal liver metastases: a comparative study based on single-center experience of 319 cases.
        Ann Surg Oncol. 2017; 24: 1557-1568
        • Sakai D.
        • Kanai M.
        • Kobayashi S.
        • et al.
        Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA).
        Ann Oncol. 2018; 29: viii205
        • Matsuda Y.
        • Ohkubo S.
        • Nakano-Narusawa Y.
        • et al.
        Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
        Sci Rep. 2020; 1018278
        • Kleiner D.E.
        • Brunt E.M.
        • Van Natta M.
        • et al.
        Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
        Hepatology. 2005; 41: 1313-1321
        • Takada T.
        Tokyo Guidelines 2018: updated Tokyo Guidelines for the management of acute cholangitis/acute cholecystitis.
        J Hepatobiliary Pancreat Sci. 2018; 25: 1-2
        • Ribero D.
        • Abdalla E.K.
        • Madoff D.C.
        • Donadon M.
        • Loyer E.M.
        • Vauthey J.N.
        Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome.
        Br J Surg. 2007; 94: 1386-1394
        • Corrêa D.
        • Schwartz L.
        • Jarnagin W.R.
        • et al.
        Kinetics of liver volume changes in the first year after portal vein embolization.
        Arch Surg. 2010; 145 (; discussion 354-355): 351-354
        • Olthof P.B.
        • Coelen R.J.S.
        • Wiggers J.K.
        • et al.
        High mortality after ALPPS for perihilar cholangiocarcinoma: case-control analysis including the first series from the international ALPPS registry.
        HPB. 2017; 19: 381-387
        • Ebata T.
        • Yokoyama Y.
        • Igami T.
        • Sugawara G.
        • Takahashi Y.
        • Nagino M.
        Portal vein embolization before extended hepatectomy for biliary cancer: current technique and review of 494 consecutive embolizations.
        Dig Surg. 2012; 29: 23-29
        • Fischer C.
        • Melstrom L.G.
        • Arnaoutakis D.
        • et al.
        Chemotherapy after portal vein embolization to protect against tumor growth during liver hypertrophy before hepatectomy.
        JAMA Surg. 2013; 148: 1103-1108
        • Karoui M.
        • Penna C.
        • Amin-Hashem M.
        • et al.
        Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.
        Ann Surg. 2006; 243: 1-7
        • Miyazaki M.
        • Kato A.
        • Ito H.
        • et al.
        Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not?.
        Surgery. 2007; 141: 581-588
        • Nagino M.
        • Nimura Y.
        • Nishio H.
        • et al.
        Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases.
        Ann Surg. 2010; 252: 115-123
        • Choi E.R.
        • Chung Y.H.
        • Lee J.K.
        • et al.
        Preoperative evaluation of the longitudinal extent of borderline resectable hilar cholangiocarcinoma by intraductal ultrasonography.
        J Gastroenterol Hepatol. 2011; 26: 1804-1810
        • Matsuyama R.
        • Morioka D.
        • Mori R.
        • et al.
        Our rationale of initiating neoadjuvant chemotherapy for hilar cholangiocarcinoma: a proposal of criteria for "borderline resectable" in the field of surgery for hilar cholangiocarcinoma.
        World J Surg. 2019; 43: 1094-1104